Display options
Cite
Tselis A, Khan O, Lisak RP. Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2007;3(2):259-67doi: 10.2147/nedt.2007.3.2.259.
Tselis, A., Khan, O., & Lisak, R. P. (2007). Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatric disease and treatment, 3(2), 259-67. https://doi.org/10.2147/nedt.2007.3.2.259
Tselis, Alex, et al. "Glatiramer acetate in the treatment of multiple sclerosis." Neuropsychiatric disease and treatment vol. 3,2 (2007): 259-67. doi: https://doi.org/10.2147/nedt.2007.3.2.259
Tselis A, Khan O, Lisak RP. Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2007 Apr;3(2):259-67. doi: 10.2147/nedt.2007.3.2.259. PMID: 19300558; PMCID: PMC2654627.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2007 Apr;3(2):259-67. doi: 10.2147/nedt.2007.3.2.259.

Glatiramer acetate in the treatment of multiple sclerosis.

Neuropsychiatric disease and treatment

Alex Tselis, Omar Khan, Robert P Lisak

Affiliations

  1. Division of Neuroimmunology, Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA.

PMID: 19300558 PMCID: PMC2654627 DOI: 10.2147/nedt.2007.3.2.259

Abstract

Glatiramer acetate is an immunomodulating drug used in the treatment of multiple sclerosis. It consists of a copolymer of amino acid residues in the same stoichiometric proportions as in myelin basic protein. Its mechanism of action is not entirely known and is probably multifaceted, with deletion of some immune cell populations and stimulation of others in these patients. Some mechanisms involve neuroprotectant effects. There is ample evidence of its efficacy in relapsing-remitting disease, using both clinical and imaging measures of disease activity, and in this paper we review the clinical and basic studies of this drug. Finally we discuss how some of its neuroprotectant effects may be useful in neurodegeneration such as is seen in more advanced cases of multiple sclerosis and other diseases such as amyotrophic lateral sclerosis and Parkinson's disease.

Keywords: glatiramer acetate; multiple sclerosis; neurodegeneration

References

  1. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4872-6 - PubMed
  2. Immunol Today. 1999 Dec;20(12):561-7 - PubMed
  3. Brain. 1999 Jan;122 ( Pt 1):17-26 - PubMed
  4. Lancet Neurol. 2005 Sep;4(9):567-75 - PubMed
  5. Lancet Neurol. 2005 Feb;4(2):75-6; discussion 76-7 - PubMed
  6. Brain. 2005 Nov;128(Pt 11):2705-12 - PubMed
  7. J Mol Med (Berl). 2005 Nov;83(11):904-16 - PubMed
  8. J Neuroimmunol. 1996 Feb;64(2):209-17 - PubMed
  9. Mult Scler. 2004 Jun;10 Suppl 1:S65-71; discussion S71-2 - PubMed
  10. Ann Neurol. 1982 Mar;11(3):317-9 - PubMed
  11. Neurology. 2002 Oct 22;59(8):1284-6 - PubMed
  12. Ann Neurol. 2001 Sep;50(3):389-400 - PubMed
  13. Neurology. 1998 Mar;50(3):701-8 - PubMed
  14. J Exp Med. 1935 Apr 30;61(5):689-702 - PubMed
  15. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9435-40 - PubMed
  16. J Immunol. 2003 May 1;170(9):4483-8 - PubMed
  17. Brain. 2002 Nov;125(Pt 11):2381-91 - PubMed
  18. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4790-5 - PubMed
  19. Mult Scler. 2005 Dec;11(6):646-51 - PubMed
  20. J Neurol Sci. 1977 Apr;31(3):433-8 - PubMed
  21. J Neurol Sci. 2003 Nov 15;215(1-2):37-44 - PubMed
  22. N Engl J Med. 1987 Aug 13;317(7):408-14 - PubMed
  23. J Neuroimmunol. 2001 Dec 3;121(1-2):102-10 - PubMed
  24. J Clin Invest. 2002 Mar;109(5):641-9 - PubMed
  25. Neurology. 1983 Nov;33(11):1444-52 - PubMed
  26. Acta Neurol Scand. 2005 Jan;111(1):42-7 - PubMed
  27. J Neuroimmunol. 2001 Apr 2;115(1-2):152-60 - PubMed
  28. Neurology. 1991 Apr;41(4):533-9 - PubMed
  29. Mult Scler. 2001 Aug;7(4):209-19 - PubMed
  30. Mult Scler. 2003 Dec;9(6):592-9 - PubMed
  31. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10821-6 - PubMed
  32. Brain. 2003 Dec;126(Pt 12):2638-47 - PubMed
  33. J Neuroimmunol. 2000 Aug 1;108(1-2):201-6 - PubMed
  34. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11472-7 - PubMed
  35. Neurology. 1995 Jul;45(7):1268-76 - PubMed
  36. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7452-7 - PubMed
  37. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7446-51 - PubMed
  38. Ann Neurol. 2001 Mar;49(3):290-7 - PubMed
  39. Ann Neurol. 1999 Aug;46(2):144-60 - PubMed
  40. Ann Neurol. 2000 Jun;47(6):707-17 - PubMed
  41. Neurology. 2001 Aug 28;57(4):731-3 - PubMed
  42. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):137-41 - PubMed
  43. Cochrane Database Syst Rev. 2004;(1):CD004678 - PubMed
  44. J Neurol Sci. 1983 Dec;62(1-3):281-93 - PubMed
  45. Immunol Lett. 1996 Apr;50(1-2):1-15 - PubMed
  46. J Exp Med. 1999 Mar 1;189(5):865-70 - PubMed
  47. Brain. 2004 Jun;127(Pt 6):1370-8 - PubMed
  48. J Clin Invest. 2000 Apr;105(7):967-76 - PubMed
  49. Neurology. 1991 Aug;41(8):1317-9 - PubMed
  50. Clin Diagn Lab Immunol. 2001 Nov;8(6):1196-203 - PubMed
  51. Brain. 2001 Apr;124(Pt 4):705-19 - PubMed
  52. J Immunol. 2004 Jun 1;172(11):7144-53 - PubMed
  53. J Neuroimmunol. 2002 Feb;123(1-2):188-92 - PubMed
  54. Neurology. 2000 Feb 22;54(4):813-7 - PubMed
  55. Mult Scler. 2003 Aug;9(4):349-55 - PubMed
  56. Neurology. 2004 Apr 27;62(8):1432-4 - PubMed
  57. Lancet Neurol. 2005 Feb;4(2):74-5; discussion 76-7 - PubMed
  58. Mult Scler. 2001 Feb;7(1):43-7 - PubMed
  59. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634-9 - PubMed

Publication Types